Submit Your Feeds

Business News • PR NewsWire • Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System

Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System

BASKING RIDGE, N.J., April 3, 2011 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company pioneering the development of antithrombotic aptamers with active control agents, announced today the primary results of the RADAR Phase 2b clinical trial of the company's lead product, the anticoag

View More : http://www.prnewswire.com/news-releases/regado-biosciences-inc-presents-results-of-the-radar-phase-2b-clinical-trial-of-...
Releted News by prnewswire
Boston Scientific ION™ Platinum Chromium Stent System Demonstrates Strong Performance in Analysis of PERSEUS and TAXUS ATLAS Clinical Trial Data
Pipes, Plants, Water and Cooling
ORFLO Launches First Hands-free Mini Automated Cell Counter
Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
Potential Treatment Found for Debilitating Bone Disease in Wounded Soldiers and Children
Major New Study Shows Aortic Valve Replacement Via Catheter Produces Better Outcomes Than Traditional Open-Heart Surgery
Gulfstream Identifies Employees Killed in G650 Crash
Home Sitemap Contact Us
© businessNewsNewsNews.com